{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:35:30Z","timestamp":1784043330049,"version":"3.55.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>NK-large granular lymphocytic leukemia (NK-LGLL) is a rare clonal lymphoproliferative disease of natural killer (NK) cells. In refractory cases, traditional chemotherapy regimens and immunosuppressive drugs often prove ineffective. Hematopoietic stem cell transplantation (HSCT) offers the opportunity to rebuild the immune system, but carries significant risks, including graft-versus-host disease (GVHD). Consequently, alternative therapeutic strategies need to be investigated. A recent study published in The Lancet reported on the use of golidocitinib in the treatment of relapsed or peripheral T-cell lymphoma. Notably, this represents the first clinical report demonstrating the efficacy of golidocitinib in managing intractable NK-large granular lymphocytic leukemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>In this study, we present a case of a 53-year-old male with NK-LGLL who achieved successful therapeutic outcomes with golidocitinib administration. The patient had a documented history of chronic gastritis and was admitted with symptoms of fatigue and chest tightness. Despite receiving various treatments such as methotrexate, cyclosporin, cyclophosphamide, and thalidomide, the patient exhibited treatment refractoriness. However, after initiating treatment with golidocitinib, the patient\u2019s blood count improved remarkedly after a single treatment cycle, obviating the need for blood transfusions. The patient maintained golidocitinib treatment without experiencing any serious complications. This is the first reported case demonstrating the efficacy of golidocitinib therapy in treating NK-LGLL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case highlights the clinical relevance of golidocitinib in developing novel therapeutic strategies for NK-LGLL. Moreover, this treatment option presents the potential as either a bridging therapy or alternative to allo-HSCT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1632803","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T05:33:37Z","timestamp":1755149617000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Golidocitinib was used for the first time to treat refractory NK-Large Granular lymphocytic leukemia with a STAT3 mutation, accompanied by hemolytic anemia: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Hongyuan","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimo","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-692590","article-title":"LGL leukemia: from pathogenesis to treatment","volume":"129","author":"Lamy","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2011.01374.x","article-title":"State of the art in natural killer cell Malignancies","volume":"34","author":"Semenzato","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006721","article-title":"Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells","volume":"137","author":"Pastoret","year":"2021","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu369","article-title":"Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients","volume":"25","author":"Poullot","year":"2014","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.821382","article-title":"Toward a better classification system for NK-LGL disorders","volume":"12","author":"Drillet","year":"2022","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1182\/blood-2012-07-441378","article-title":"Intrinsic and extrinsic mechanisms contribute to maintain the JAK\/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia","volume":"121","author":"Teramo","year":"2013","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005831","article-title":"Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias","volume":"138","author":"Olson","year":"2021","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1309\/Q49CRJ030L22MHLF","article-title":"The immunophenotypic attributes of NK cells and NK-cell lineage lymphoproliferative disorders","volume":"127","author":"Morice","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2144194","DOI":"10.1080\/09537104.2022.2144194","article-title":"Prevalence and significance of large granular lymphocytes in patients with immune thrombocytopenia","volume":"34","author":"Gabe","year":"2023","journal-title":"Platelets"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.8881","article-title":"Clinical features, pathogenesis, and treatment of large granular lymphocyte leukemias","volume":"56","author":"Oshimi","year":"2017","journal-title":"Intern Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-3-263","article-title":"Large granular lymphocyte leukemia","volume":"11","author":"Sokol","year":"2006","journal-title":"Oncologist"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e04533","DOI":"10.1002\/ccr3.4533","article-title":"A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia","volume":"9","author":"Zawit","year":"2021","journal-title":"Clin Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01296-0","article-title":"STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation","volume":"35","author":"Kim","year":"2021","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111711","article-title":"STAT3 dysregulation in mature T and NK cell lymphomas","volume":"11","author":"Seffens","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0644-0","article-title":"Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients","volume":"34","author":"Barila","year":"2020","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.3390\/cancers12123508","article-title":"Stat3 and stat5b mutations in t\/nk-cell chronic lymphoproliferative disorders of large granular lymphocytes (lgl): association with disease features","volume":"12","author":"Munoz-Garcia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1632803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T05:33:38Z","timestamp":1755149618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1632803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2025.1632803"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1632803","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"article-number":"1632803"}}